Response-Adaptive Phase II Study of Daratumumab Combined with Carfilzomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma

被引：1
|
作者：
Bhutani, Manisha
House, Monika
He, Jiaxian
Atrash, Shebli
Foureau, David M.
Paul, Barry
Friend, Reed
Symanowski, James T.
Norek, Sarah
Begic, Xhevahire
Acampora, Donna
Farmer, Katherine K.
Syfert, Carrie Ann
Pineda-Roman, Mauricio
Voorhees, Peter
Usmani, Saad Z.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-138485
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] A Phase 2 Study of Extended Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
    Derman, Ben A.
    Major, Ajay
    Rosenblatt, Jacalyn
    Avigan, David
    Rampurwala, Murtuza M.
    Alcantar, Luis
    Libao, Bernadette M.
    McIver, Amanda
    Andreatos, Evangelia
    Major, Sarah
    Wolfe, Brittany
    Gorski, Martha
    Karrison, Theodore G.
    Stefka, Andrew
    Jakubowiak, Andrzej
    [J]. BLOOD, 2021, 138
  • [2] Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
    Jakubowiak, Andrzej
    Usmani, Saad Z.
    Krishnan, Amrita
    Lonial, Sagar
    Comenzo, Raymond L.
    Wang, Jianping
    de Boer, Carla
    Deraedt, William
    Weiss, Brendan M.
    Schecter, Jordan M.
    Chari, Ajai
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (10): : 701 - 710
  • [3] Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant
    Derman, Benjamin A.
    Cooperrider, Jennifer
    Rosenblatt, Jacalyn
    Avigan, David E.
    Rampurwala, Murtuza
    Barnidge, David
    Major, Ajay
    Karrison, Theodore
    Jiang, Ken
    Ramsland, Aubrianna
    Kubicki, Tadeusz
    Jakubowiak, Andrzej J.
    [J]. BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [4] Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) and Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (DKRd) As Induction Therapy in Newly Diagnosed Multiple Myeloma
    Tan, Carlyn
    Maclachlan, Kylee H.
    Nemirovsky, David
    Derkach, Andriy
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi A.
    Rajeeve, Sridevi
    Patel, Dhwani
    Shekarkhand, Tala
    Rueda, Colin
    Lahoud, Oscar Boutros
    Shah, Gunjan L.
    Scordo, Michael
    Chung, David
    Landau, Heather
    Giralt, Sergio A.
    Lesokhin, Alexander
    Usmani, Saad Z.
    [J]. BLOOD, 2023, 142
  • [5] Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Tan, Carlyn Rose
    Maclachlan, Kylee
    Nemirovsky, David
    Derkach, Andriy
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi
    Patel, Dhwani
    Shekarkhand, Tala
    Rueda, Colin
    Lahoud, Oscar
    Shah, Gunjan
    Scordo, Michael
    Chung, David
    Landau, Heather
    Giralt, Sergio
    Usmani, Saad
    Lesokhin, Alexander
    Korde, Neha
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S127 - S127
  • [6] Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
    Kumar, Shaji K.
    Kapoor, Prashant
    Laplant, Betsy
    Phuong-Dung, Liang
    Muchtar, Eli
    Buadi, Francis K.
    Gonsalves, Wilson I.
    Malave, Gabriella C.
    Vossen, Alanna M.
    Dingli, David
    Go, Ronald S.
    Warsame, Rahma M.
    Kourelis, Taxiarchis
    Hwa, Yi L.
    Fonder, Amie
    Hobbs, Miriam A.
    Lust, John A.
    Lacy, Martha Q.
    Dispenzieri, Angela
    Hayman, Suzanne R.
    Leung, Nelson
    Rajkumar, S. Vincent
    Gertz, Morie A.
    [J]. BLOOD, 2020, 136
  • [7] Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma
    Forsberg, Peter A.
    Rossi, Adriana C.
    Boyer, Angelique
    Tegnestam, Linda
    Pearse, Roger N.
    Perry, Arthur
    Pekle, Karen A.
    Jayabalan, David
    Ely, Scott
    Boussi, Leora
    Sherbenou, Daniel W.
    Willianns, Colt
    Allan, John N.
    Coleman, Morton
    Niesvizky, Ruben
    Mark, Tomer M.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (05) : 539 - 545
  • [8] Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma
    Costa, Luciano J.
    Chhabra, Saurabh
    Medvedova, Eva
    Dholaria, Bhagirathbhai R.
    Schmidt, Timothy M.
    Godby, Kelly N.
    Silbermann, Rebecca
    Dhaka, Binod
    Bal, Susan
    Gid, Smith
    D'Souza, Anita
    Hall, Aric
    Hardwick, Pamela
    Omel, James
    Cornell, Robert F.
    Had, Parameswaran
    Callander, Natalie S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (25) : 2901 - +
  • [9] Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone (CRd) in Newly Diagnosed Multiple Myeloma (MM) Patients
    Korde, Neha
    Zingone, Adriana
    Kwok, Mary
    Manasanch, Elisabet E.
    Costello, Rene
    Zuchlinski, Diamond
    Mulquin, Marcia
    Maric, Irina
    Calvo, Katherine R.
    Braylan, Raul C.
    Yuan, Constance
    Tembhare, Prashant Ramesh
    Stetler-Stevenson, Maryalice
    Arthur, Diane C.
    Raffeld, Mark
    Xi, Liqiang
    Choyke, Peter
    Kurdziel, Karen
    Lindenberg, Liza
    Steinberg, Seth M.
    Roschewski, Mark
    Landgren, Ola
    [J]. BLOOD, 2012, 120 (21)
  • [10] Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma
    Jasielec, Jagoda K.
    Kubicki, Tadeusz
    Raje, Noopur
    Vij, Ravi
    Reece, Donna
    Berdeja, Jesus
    Derman, Benjamin A.
    Rosenbaum, Cara A.
    Richardson, Paul
    Gurbuxani, Sandeep
    Major, Sarah
    Wolfe, Brittany
    Stefka, Andrew T.
    Stephens, Leonor
    Tinari, Kathryn M.
    Hycner, Tyler
    Rojek, Alexandra E.
    Dytfeld, Dominik
    Griffith, Kent A.
    Zimmerman, Todd M.
    Jakubowiak, Andrzej J.
    [J]. BLOOD, 2020, 136 (22) : 2513 - 2523
12345